23 completed. 23 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 23 |
| Phase 2 | 2 | Completed 2 |
Follow Coronary Heart Disease: new trials by email Literature Review of Coronary Heart Disease trials Research Report on Coronary Heart Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) dalcetrapib, placebo - Coronary Heart Disease | Phase 3 | Completed | Hoffmann-La Roche | 300 | 2011-03-01 | 2019-07-30 |
| Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery Remote ischaemic preconditioning, Control - Coronary Heart Disease | Phase 3 | Completed | University College, London | 1612 | 2010-11-01 | 2015-05-29 |
| Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease Ateronon, Placebo - Coronary Heart Disease | Phase 3 | Completed | Brigham and Women's Hospital | 213 | 2009-07-01 | 2014-08-19 |
| Treatment of Coronary Heart Disease With Amiloride Amiloride, Nitrates, clopidogrel, aspirin, statins - Coronary Heart Disease | Phase 2 / Phase 3 | Completed | University of Carabobo | 70 | 2009-02-01 | 2012-06-11 |
| Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis Mipomersen, Placebo - Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Completed | Kastle Therapeutics, LLC | 58 | 2009-01-01 | 2016-09-09 |
| Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients Mipomersen sodium, Placebo - Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Completed | Kastle Therapeutics, LLC | 158 | 2008-11-01 | 2016-09-09 |
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome, Placebo - Coronary Heart Disease | Phase 3 | Completed | Hoffmann-La Roche | 15871 | 2008-04-01 | 2020-01-03 |
| Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood ABT-335, Placebo, Atorvastatin - Coronary Artery Disease, Coronary Heart Disease | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 682 | 2008-02-01 | 2018-07-02 |
| Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood ABT-335, placebo, atorvastatin - Dyslipidemias, Coronary Heart Disease | Phase 3 | Completed | Abbott | 543 | 2008-02-01 | 2011-06-13 |
| 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe Rosuvastatin (Crestor), Ezetimibe, Simvastatin - Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Completed | AstraZeneca | 1743 | 2007-08-01 | 2011-05-13 |
| Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin - Cardiovascular Disease, Peripheral Arterial Disease | Phase 3 | Completed | University of Oxford | 25673 | 2007-01-01 | 2014-02-28 |
| Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 1911 | 2006-09-01 | 2009-07-23 |
| Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors pitavastatin, simvastatin - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Kowa Research Europe | 178 | 2006-06-01 | 2010-02-02 |
| Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel impact on VASP test - Coronary Heart Disease | Phase 3 | Completed | University Hospital, Brest | 120 | 2006-06-01 | 2008-08-25 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Atorvastatin, Placebo - Mixed Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 613 | 2006-03-01 | 2009-06-03 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Simvastatin, Placebo - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 657 | 2006-03-01 | 2009-06-03 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Rosuvastatin Calcium, Placebo - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 1445 | 2006-03-01 | 2009-06-10 |
| ESCAP: Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting Supervised exercise on a stationary bicycle, 3-5 days a week, Secondary prevention program for coronary heart disease - Coronary Heart Disease | Phase 3 | Completed | Basque Health Service | 97 | 2005-01-01 | 2011-06-01 |
| Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg Rosuvastatin, Ezetimibe - Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Completed | AstraZeneca | 2004-06-01 | 2009-03-26 | |
| Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks Rosuvastatin, Atorvastatin - Hypercholesterolemia, Coronary Heart Disease | Phase 3 | Completed | AstraZeneca | 2003-04-01 | 2009-03-16 |
Showing 20 of 23. Sign in to see all of them.
Coronary Disease (23) · Dyslipidemias (7) · Hypercholesterolemia (6) · Atherosclerosis (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hyperglycemia (1) · Motor Activity (1) · Peripheral Arterial Disease (1) · Stroke (1) · Weight Loss (1)
Heart Diseases (23) · Myocardial Ischemia (23) · Vascular Diseases (23) · Cardiovascular Diseases (22) · Metabolic Diseases (14) · Nutritional and Metabolic Diseases (14) · Lipid Metabolism Disorders (12) · Hyperlipidemias (6) · Dyslipidemias (5) · Arterial Occlusive Diseases (4) · Arteriosclerosis (4) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Atherosclerosis (1) · Behavior (1)
2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (6) · Atorvastatin (5) · Rosuvastatin Calcium (5) · Simvastatin (5) · Ezetimibe (3) · Fenofibrate (2) · dalcetrapib (2) · fenofibric acid (2) · mipomersen (2) · Amiloride (1) · Aspirin (1) · Clopidogrel (1) · Estrogens, Conjugated (USP) (1) · Ezetimibe, Simvastatin Drug Combination (1) · Gemfibrozil (1)
Abbott (5) · AstraZeneca (3) · Hoffmann-La Roche (2) · Kastle Therapeutics, LLC (2) · AbbVie (prior sponsor, Abbott) (1) · Basque Health Service (1) · Brigham and Women's Hospital (1) · Kowa Research Europe (1) · Lund University Hospital (1) · University College, London (1) · University Hospital, Brest (1) · University of California, San Francisco (1) · University of Carabobo (1) · University of Oxford (1) · VA Office of Research and Development (1)
United States (14) · United Kingdom (5) · Netherlands (4) · Czechia (3) · Spain (3) · Sweden (3) · Argentina (2) · Brazil (2) · Canada (2) · Denmark (2) · France (2) · Germany (2) · South Africa (2) · Venezuela (2) · Australia (1)
Maureen Kelly, MD (2) · Antonio J Delgado-Leon, MD (1) · Antonio R Delgado-Almeida, MD, FAHA, FACC, APS (1) · Carlos L Delgado-Leon, MD (1) · Christie M Ballantyne, MD FACP FACC (1) · Christine Ballantyne, MD (1) · Colin Baigent (1) · Derek J Hausenloy, MD PhD (1) · Dr. Lawrence Leiter (1) · Dragos Budinski, MD (1) · Hanna E. Bloomfield, MD MPH (1) · Howard D. Sesso, ScD, MPH (1) · Jane Armitage (1)
PMID 18783301, PMID 20136164, PMID 20573750, PMID 22263674, PMID 25614280, PMID 10438259, PMID 12117730, PMID 12456232, PMID 17583796, PMID 18206732, PMID 18996523, PMID 19576325, PMID 19958854, PMID 20738227, PMID 20934572, PMID 21118562, PMID 21174145, PMID 21874537, PMID 22186969, PMID 22345126, PMID 22622962, PMID 23126252, PMID 23152839, PMID 24013058, PMID 24142481, PMID 25014686, PMID 25252696, PMID 25583994, PMID 26022813, PMID 26436207, PMID 27407053, PMID 27418594, PMID 27578134, PMID 28073769, PMID 29071331, PMID 29449329, PMID 30821829, PMID 31447131, PMID 31805983, PMID 31927126, PMID 32144166, PMID 8806347, PMID 9778079
2008 (1)